



Webinar Series: The Role of Vaccination in
Maintaining Health and the Economy During
Pandemics

Financing Life-Course Immunization for COVID-19 Response & Beyond

6 May 2021 20:00 (Washington, DC)

7 May 2021 9:00 (Singapore)

13:00 (Auckland)



Anupama Tantri

Executive Director of Vaccine Policy Development
MSD



Webinar Series: The Role of Vaccination in
Maintaining Health and the Economy During
Pandemics

Financing Life-Course Immunization for COVID-19 Response & Beyond

6 May 2021 20:00 (Washington, DC)

7 May 2021 9:00 (Singapore)

13:00 (Auckland)



Dr. Chunhuei Chi
Professor
Oregon State University

Mobilizing Resources to Enable Urgent COVID-19 Mass Vaccination

A Presentation at APEC's
Life Sciences Innovation Forum
Financing Life-Course Immunization for COVID-19
Response & Beyond
Webinar

May 7th , 2021

Chunhuei Chi, MPH, Sc.D.

Director, Center for Global Health

Professor, Global Health Program

Professor, Health Management & Policy Program

College of Public Health and Human Sciences

Oregon State University



Oregon State University
Center for Global Health



**Life Sciences
Innovation Forum**

Key Questions


1.What steps are needed to mobilize resources to enable urgent COVID-19 mass vaccination?

2.What types of needs must emergency vaccination funding cover (e.g., more vaccinators, training, communication campaigns, data and tracking systems, new vaccination sites)?



Share of people who received at least one dose of COVID-19 vaccine

Share of the total population that received at least one vaccine dose. This may not equal the share that are fully vaccinated if the vaccine requires two doses.



Source: Official data collated by Our World in Data

CC BY

PROCUREMENT




DELIVERY

AVAILABILITY




ACCESSIBILITY

VACCINATION




PROTECTION

Mass Vaccination and Resource Mobilization



APEC Economies' Per Capita HC Expenditure, PPP USD, 2018



Data Source: World Bank, 2021

<https://data.worldbank.org/indicator/SH.XPD.CHEX.PC.CD> ,

Financing Source for COVID-19 Vaccination

Domestic

- **MOH Fiscal**
- **MOH Emergency**
- **MOF/MOE Emergency**
- **Extra-Budgetary Mechanism**
- **Trust Funds and Bonds**
- **In-kind Resources**

External

- **ADB**
- **World Bank**
- **COVAX**
- **Bilateral**
- **Multilateral**
- **Grants and Loans**
- **Bonds**

Planning for the Future

- 1. An opportunity to strengthen health system and infrastructure beyond the pandemic**
- 2. Contextualization of resource mobilization and financing**
- 3. Vaccination to improve, rather to exacerbate social and health inequity**
- 4. Collaboration within and beyond APEC**



Webinar Series: The Role of Vaccination in
Maintaining Health and the Economy During
Pandemics

Financing Life-Course Immunization for COVID-19 Response & Beyond

6 May 2021 20:00 (Washington, DC)

7 May 2021 9:00 (Singapore)

13:00 (Auckland)



Dr. Mursaleena Islam
Program Director
Thinkwell

How can we ensure adequate financing for routine immunization in the context of COVID-19?

Mursaleena Islam, Ph.D. | APEC Webinar | May 2021

Securing the resources for routine immunization and COVID-19 priorities requires **robust, contextually-relevant, and actionable economic evidence**

Drawing on Relevant Case Studies

- 1 How much does it cost to deliver routine immunization in the COVID-19 context?
- 2 What is the cost of delivering COVID vaccines?
- 3 How much financing is available for routine immunization?

Case Study


1

How much does it cost to deliver routine immunization in the COVID-19 context?


Background: COVID precautions including **masks, gloves and other infection control measures** were anticipated to increase the cost of delivering routine immunization services, though decision makers had little evidence on the likely scale or main drivers of such costs




Working across **8 countries**, we set out to assess the **incremental additional costs** of delivery



Analyzed **historical immunization expenditure data** for each country to establish 'baseline'



Built a **unit-cost database** for key commodities from sources including the UNICEF Supply Catalogue



Developed a **dynamic model** to project delivery costs across three implementation scenarios




Results and Impact: Our projections showed that the costs of delivering routine immunizations by outreach **could increase by 20-129%**. These data are now used by national governments and development partners to better anticipate and advocate for additional budget needs

Case Study

2

What is the cost of delivering COVID vaccines?

Background: COVAX member countries and donors required rapid evidence on the **non-antigen delivery costs of COVID vaccines** to better inform **planning and advocacy efforts**.



Goal: To determine **incremental delivery costs** for COVID vaccines across all 92 AMC countries

Supported the **COVAX Costing TWG** to build and test assumptions on population coverage and scale-up strategies

Modelled costs at **global/regional levels** (tech) as well as at **country level** (transport, cold chain, etc.)

Developed robust estimates of **costs per dose, costs per country** as well as **total costs across all AMC countries**

Results and Impact: Country-level delivery costs amount to **US\$2.82 per fully vaccinated person**. The World Bank used these findings to conduct a fiscal space analysis to support resource allocation and prioritization.

Case Study

3

How much financing is available for routine immunization?

Background: The Indonesian Ministry of Health (IMoH) acted rapidly at the onset of the pandemic to **reallocate funding from routine service delivery toward COVID response**



Goal: To determine the impacts of **COVID response reallocations** on **local-level budgets for routine immunization**



Worked with **Government and local-level managers** to analyze pre- and post pandemic budgets



Cross-district analysis of financing adjustment for essential services including **routine immunization**



Combined **budget analytics** with **interviews with service providers** to **determine qualitative impact** on services

Results and Impact: The budget for routine immunization declined across all districts assessed, through the magnitude of the decline varied. The combination of quantitative and qualitative outputs gave decision makers rich evidence to support budget advocacy efforts

Securing the resources for routine immunization and COVID-19 priorities requires **robust, contextually-relevant, and actionable economic evidence**

1

Evidence needs vary

Economic and financial costing

Cost-benefit analysis

Investment cases

2

Context is crucial

Payer perspectives

Local expertise

Laser focus on usability

3

Dissemination is key

Government counterparts

Implementing partners

Academic community



ThinkWell is an organization dedicated to improving the health and well-being of society as a means to achieve global prosperity. Since 2011, we have supported over 30 countries to achieve long-lasting improvements to their health systems.

Find out more at **thinkwell.global**

Contact speaker, Mursaleena Islam:

 **mislam@thinkwell.global**



Webinar Series: The Role of Vaccination in
Maintaining Health and the Economy During
Pandemics

Financing Life-Course Immunization for COVID-19 Response & Beyond

6 May 2021 20:00 (Washington, DC)

7 May 2021 9:00 (Singapore)

13:00 (Auckland)




Dr. Ping-Ing Lee
Professor
National Taiwan University

Mobilizing Diverse & Sustainable Financing to Achieve Immunization Across the Life-Course

Ping-Ing Lee


The government should be responsible for promoting immunization



- Constitutions
 - 156: ... should adopt and execute policies to **improve welfare of women and children**
 - 157: ...should promote **preventive medicine**

Source of funding for NIP program, Taipei

NT\$ X 10³



Health interventions in competition

Long-term care

Health insurance

Rare disease

Nutrition policy

Betel nut control

Hospital accreditation

Obesity prevention

Precision medicine

Drug control

Tabaco control

Cancer screening

HIV prevention

New technology

Health insurance

Border quarantine

Health screening

Age-friendly

TB control

Prenatal care


Infection control

Immunization

Cost-effectiveness analysis

- Disability-adjusted life year (DALY):
 - Assessment of global burden of disease analysis
 - Combines years of life lost due to premature mortality and years of life lost due to time lived in states of less than full health.
- DALY averted (WHO)
 - $< \text{per capita GNI} \times 1$: **very cost-effective**
 - $\text{Per capita GNI} \times 1-3$: **cost-effective**
 - $> \text{Per capita GNI} \times 3$: **not cost-effective**
- GDP of Taiwan (2007): \$29,800

Most cost-effective analyses ignored the impacts other than finance




Pap: papanicolaou smear; CIN: cervical intraepithelial neoplasia; HPV: human papilloma virus

Independent budget for immunization

□ Immunization Funds since 2010

Vaccine	'18	'19	'20	'21	'22	'23
Hepatitis A vaccine for children	○	○	○	○	○	○
Pneumococcal vaccine for ≥ 75 yrs		○	○	○	○	○
Pneumococcal vaccine for high-risk population		○	○	○	○	○
Hepatitis B immune globulin for neonates born to HBeAg(-) carrier mothers		○	○	○	○	○
Pneumococcal vaccine for ≥ 65 yrs			○	○	○	○
Rotavirus vaccine for infants			Low income	○	○	○
Pneumococcal vaccine for at-risk population					○	○
Hepatitis A vaccine for adolescents						○

Vaccine Funds since 2010, Taipei



Vaccine donations

GAVI, since 2000



CAREERS CONTACT ETHICS HOTLINE RFP MYGAVI DONATE FRENCH

Enter keyword here... Search



HOME ABOUT GAVI SUPPORT COUNTRY HUB FUNDING & FINANCE RESULTS & EVIDENCE LIBRARY & NEWS

You are here: About Gavi ▾

About Gavi, the Vaccine Alliance

Created in 2000, Gavi is an international organisation - a global Vaccine Alliance, bringing together public and private sectors with the shared goal of creating equal access to new and underused vaccines for children living in the world's poorest countries.



Why invest in vaccines?

How Gavi works

ABOUT GAVI

Gavi's mission

Gavi's strategy

Value of vaccination

Gavi's partnership model

Gavi's business model

Global health and development

Governing Gavi

Gavi members include




G.Q.

<http://www.gavi.org/about/governance/programme-policies/vaccine-donation/>

Vaccine donations

UNICEF




70 YEARS FOR EVERY CHILD

WHO WE AREWHAT WE DO ▾WHERE WE WORK ▾PRESS CENTRE ▾STATISTICSBLOGS

Who we are

UNICEF works for a world in which every child has a fair chance in life.


[About UNICEF](#)



© UNICEF/NYHQ/ISTAP/Photo: UNICEF

From distributing lifesaving aid to children in the aftermath of World War II to fighting Ebola, UNICEF has been working for children for almost 70 years.

[Our history](#)



Children need your help

Children worldwide need your help right now. Please donate what you can today.

[DONATE NOW](#)

UNICEF believes:

All children have a right to survive, thrive and fulfill their potential - to the benefit of a better world.

That means equal access to services and care that can make all the difference in children's lives. It means working to achieve gender fairness and equality. [Read about UNICEF's gender action plan.](#)

[See how UNICEF works](#)


NT\$7.1 billion donated to a University Biomedicine to Fight Cancer

Central Agency,
Oct 8, 2015



Religious giving, Taipei

Questionnaire survey, 1994-2009



Awareness! Awareness! Awareness!


- ❑ Increased **awareness** of the importance of vaccine and vaccine-preventable disease:
 - ↓ Vaccine hesitancy
 - ↑ Vaccine acceptance
 - ↑ Vaccine donation
 - ↑ motivation of stakeholders to support vaccination program
- ❑ Measures to increase awareness:
 - ❑ **Public education**: starting from primary schools
 - ❑ **Media education**
 - ❑ **Medical education**
 - ❑ **Continued medical education**

Parents' attitude toward copayment for immunization

N=1,560, TIVS, Taipei, 2014




Question:
How much will
you be willing to
pay for a vaccine
with a copayment
strategy?




Areas with rotavirus vaccine in NIP

N-81, May 1, 2016




Areas with pneumococcal conjugate vaccine in NIP

SAGE, WHO, Oct. 18, 2017



Areas with human papillomavirus vaccine in NIP

N=80, May, 2018, WHO



Joint Expert Forum for Prevention of Pneumococcal Diseases in Children in Asia



Thanks....

Alishan